Does the media refer more to OCUL or TTRX?

In the previous week, Ocular Therapeutix had 13 more articles in the media than Turn Therapeutics. MarketBeat recorded 14 mentions for Ocular Therapeutix and 1 mentions for Turn Therapeutics. Turn Therapeutics' average media sentiment score of 0.41 beat Ocular Therapeutix's score of 0.08 indicating that Turn Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Turn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TTRX or ANIP?

In the previous week, ANI Pharmaceuticals had 3 more articles in the media than Turn Therapeutics. MarketBeat recorded 4 mentions for ANI Pharmaceuticals and 1 mentions for Turn Therapeutics. ANI Pharmaceuticals' average media sentiment score of 0.52 beat Turn Therapeutics' score of 0.41 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Turn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ANI Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, RAPP or TTRX?

Turn Therapeutics is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rapport Therapeutics N/A N/A -$111.48M -$3.04 N/A Turn Therapeutics N/A N/A -$3.19M -$0.29 N/A

Is RAPP or TTRX more profitable?

Rapport Therapeutics' return on equity of -29.02% beat Turn Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rapport Therapeutics N/A -29.02% -27.37% Turn Therapeutics N/A -230.84% -53.19%

Does the media prefer RAPP or TTRX?

In the previous week, Rapport Therapeutics had 7 more articles in the media than Turn Therapeutics. MarketBeat recorded 8 mentions for Rapport Therapeutics and 1 mentions for Turn Therapeutics. Rapport Therapeutics' average media sentiment score of 0.72 beat Turn Therapeutics' score of 0.41 indicating that Rapport Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Turn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, TTRX or GHRS?

Turn Therapeutics is trading at a lower price-to-earnings ratio than GH Research, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Turn Therapeutics N/A N/A -$3.19M -$0.29 N/A GH Research N/A N/A -$48.26M -$1.00 N/A

Is TTRX or GHRS more profitable?

GH Research's return on equity of -20.86% beat Turn Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Turn Therapeutics N/A -230.84% -53.19% GH Research N/A -20.86% -20.12%

Does the media favor TTRX or GHRS?

In the previous week, Turn Therapeutics and Turn Therapeutics both had 1 articles in the media. GH Research's average media sentiment score of 0.67 beat Turn Therapeutics' score of 0.41 indicating that GH Research is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Turn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GH Research 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TTRX or INVA more profitable?

Innoviva has a net margin of 81.19% compared to Turn Therapeutics' net margin of 0.00%. Innoviva's return on equity of 28.03% beat Turn Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Turn Therapeutics N/A -230.84% -53.19% Innoviva 81.19% 28.03% 20.19%

Does the media refer more to TTRX or INVA?

In the previous week, Turn Therapeutics had 1 more articles in the media than Innoviva. MarketBeat recorded 3 mentions for Turn Therapeutics and 2 mentions for Innoviva. Innoviva's average media sentiment score of 0.99 beat Turn Therapeutics' score of 0.41 indicating that Innoviva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Turn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Innoviva 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Turn Therapeutics (TTRX) Competitors

$13.33 +0.02 (+0.15%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$13.25 -0.08 (-0.62%)

As of 10/2/2026 07:50 PM Eastern

Compare

TTRX vs. OCUL, ANIP, RAPP, GHRS, and INVA

Should you buy Turn Therapeutics stock or one of its competitors? Turn Therapeutics's main competitors and comparable companies include Ocular Therapeutix (OCUL), ANI Pharmaceuticals (ANIP), Rapport Therapeutics (RAPP), GH Research (GHRS), and Innoviva (INVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Turn Therapeutics compare to Ocular Therapeutix?

Ocular Therapeutix (NASDAQ:OCUL) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

59.2% of Ocular Therapeutix shares are owned by institutional investors. 3.1% of Ocular Therapeutix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Turn Therapeutics has lower revenue, but higher earnings than Ocular Therapeutix. Turn Therapeutics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$52.06M	29.36	-$265.94M	-$1.42	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A

Ocular Therapeutix presently has a consensus price target of $24.33, indicating a potential upside of 249.62%. Turn Therapeutics has a consensus price target of $9.00, indicating a potential downside of 32.48%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, equities analysts plainly believe Ocular Therapeutix is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Turn Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.50

Turn Therapeutics has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -579.10%. Ocular Therapeutix's return on equity of -59.89% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-579.10%	-59.89%	-45.99%
Turn Therapeutics	N/A	-230.84%	-53.19%

In the previous week, Ocular Therapeutix had 13 more articles in the media than Turn Therapeutics. MarketBeat recorded 14 mentions for Ocular Therapeutix and 1 mentions for Turn Therapeutics. Turn Therapeutics' average media sentiment score of 0.41 beat Ocular Therapeutix's score of 0.08 indicating that Turn Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
Turn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Ocular Therapeutix beats Turn Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Turn Therapeutics compare to ANI Pharmaceuticals?

Turn Therapeutics (NASDAQ:TTRX) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

ANI Pharmaceuticals has a net margin of 11.07% compared to Turn Therapeutics' net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.37% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	-230.84%	-53.19%
ANI Pharmaceuticals	11.07%	27.37%	10.47%

In the previous week, ANI Pharmaceuticals had 3 more articles in the media than Turn Therapeutics. MarketBeat recorded 4 mentions for ANI Pharmaceuticals and 1 mentions for Turn Therapeutics. ANI Pharmaceuticals' average media sentiment score of 0.52 beat Turn Therapeutics' score of 0.41 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Turn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ANI Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ANI Pharmaceuticals has higher revenue and earnings than Turn Therapeutics. Turn Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A
ANI Pharmaceuticals	$883.37M	1.88	$78.34M	$4.64	15.56

Turn Therapeutics presently has a consensus price target of $9.00, suggesting a potential downside of 32.48%. ANI Pharmaceuticals has a consensus price target of $98.00, suggesting a potential upside of 35.77%. Given ANI Pharmaceuticals' higher possible upside, analysts plainly believe ANI Pharmaceuticals is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.50
ANI Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

ANI Pharmaceuticals beats Turn Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Turn Therapeutics compare to Rapport Therapeutics?

Rapport Therapeutics (NASDAQ:RAPP) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Rapport Therapeutics presently has a consensus price target of $66.25, suggesting a potential upside of 105.94%. Turn Therapeutics has a consensus price target of $9.00, suggesting a potential downside of 32.48%. Given Rapport Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Rapport Therapeutics is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Turn Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.50

Rapport Therapeutics' return on equity of -29.02% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-29.02%	-27.37%
Turn Therapeutics	N/A	-230.84%	-53.19%

In the previous week, Rapport Therapeutics had 7 more articles in the media than Turn Therapeutics. MarketBeat recorded 8 mentions for Rapport Therapeutics and 1 mentions for Turn Therapeutics. Rapport Therapeutics' average media sentiment score of 0.72 beat Turn Therapeutics' score of 0.41 indicating that Rapport Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Turn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Turn Therapeutics is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$3.04	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A

Summary

Rapport Therapeutics beats Turn Therapeutics on 8 of the 10 factors compared between the two stocks.

How does Turn Therapeutics compare to GH Research?

Turn Therapeutics (NASDAQ:TTRX) and GH Research (NASDAQ:GHRS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

In the previous week, Turn Therapeutics and Turn Therapeutics both had 1 articles in the media. GH Research's average media sentiment score of 0.67 beat Turn Therapeutics' score of 0.41 indicating that GH Research is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Turn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GH Research	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GH Research's return on equity of -20.86% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	-230.84%	-53.19%
GH Research	N/A	-20.86%	-20.12%

56.9% of GH Research shares are held by institutional investors. 41.6% of GH Research shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Turn Therapeutics is trading at a lower price-to-earnings ratio than GH Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A

Turn Therapeutics currently has a consensus target price of $9.00, suggesting a potential downside of 32.48%. GH Research has a consensus target price of $45.00, suggesting a potential upside of 96.16%. Given GH Research's stronger consensus rating and higher probable upside, analysts plainly believe GH Research is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.50
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

GH Research beats Turn Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Turn Therapeutics compare to Innoviva?

Turn Therapeutics (NASDAQ:TTRX) and Innoviva (NASDAQ:INVA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

99.1% of Innoviva shares are held by institutional investors. 2.0% of Innoviva shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Innoviva has higher revenue and earnings than Turn Therapeutics. Turn Therapeutics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A
Innoviva	$411.33M	3.60	$271.17M	$4.10	5.00

In the previous week, Turn Therapeutics had 1 more articles in the media than Innoviva. MarketBeat recorded 3 mentions for Turn Therapeutics and 2 mentions for Innoviva. Innoviva's average media sentiment score of 0.99 beat Turn Therapeutics' score of 0.41 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Turn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Innoviva	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Turn Therapeutics currently has a consensus price target of $9.00, suggesting a potential downside of 32.48%. Innoviva has a consensus price target of $39.25, suggesting a potential upside of 91.46%. Given Innoviva's stronger consensus rating and higher possible upside, analysts plainly believe Innoviva is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.50
Innoviva	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Innoviva has a net margin of 81.19% compared to Turn Therapeutics' net margin of 0.00%. Innoviva's return on equity of 28.03% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	-230.84%	-53.19%
Innoviva	81.19%	28.03%	20.19%

Summary

Innoviva beats Turn Therapeutics on 13 of the 15 factors compared between the two stocks.

Get Turn Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TTRX vs. The Competition

Export

Metric	Turn Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$396.48M	$12.24B	$7.14B	$13.17B
Dividend Yield	N/A	2.64%	2.53%	16.78%
P/E Ratio	-45.97	799.70	275.68	26.04
Price / Sales	N/A	842.26	658.29	101.16
Price / Cash	N/A	82.26	77.60	51.75
Price / Book	83.31	10.46	10.93	6.31
Net Income	-$3.19M	$2.84B	$3.51B	$362.16M
7 Day Performance	6.73%	-1.57%	-2.00%	-1.66%
1 Month Performance	32.37%	-5.67%	-6.15%	-4.50%
1 Year Performance	N/A	-4.73%	7.44%	2.06%

Turn Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TTRX Turn Therapeutics	1.732 of 5 stars	$13.33 +0.2%	$9.00 -32.5%	N/A	$396.48M	N/A	N/A	2
OCUL Ocular Therapeutix	2.7336 of 5 stars	$7.29 -5.0%	$25.29 +246.9%	-37.1%	$1.68B	$51.95M	N/A	325	News Coverage Analyst Forecast
ANIP ANI Pharmaceuticals	4.4482 of 5 stars	$72.96 +0.4%	$98.00 +34.3%	-19.0%	$1.67B	$883.37M	15.72	970	Insider Trade
RAPP Rapport Therapeutics	2.7481 of 5 stars	$32.83 -2.3%	$66.25 +101.8%	+12.7%	$1.61B	N/A	N/A	84	News Coverage Insider Trade
GHRS GH Research	3.0624 of 5 stars	$22.86 -2.6%	$45.00 +96.9%	+72.0%	$1.61B	N/A	N/A	73	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TTRX) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Turn Therapeutics (TTRX) Competitors

TTRX vs. OCUL, ANIP, RAPP, GHRS, and INVA

How does Turn Therapeutics compare to Ocular Therapeutix?

Summary

How does Turn Therapeutics compare to ANI Pharmaceuticals?

Summary

How does Turn Therapeutics compare to Rapport Therapeutics?

Summary

How does Turn Therapeutics compare to GH Research?

Summary

How does Turn Therapeutics compare to Innoviva?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TTRX vs. The Competition

Turn Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Turn Therapeutics (TTRX) Competitors

TTRX vs. OCUL, ANIP, RAPP, GHRS, and INVA

How does Turn Therapeutics compare to Ocular Therapeutix?

Do insiders & institutionals believe in OCUL or TTRX?

Which has stronger earnings and valuation, OCUL or TTRX?

Do analysts recommend OCUL or TTRX?

Is OCUL or TTRX more profitable?

Does the media refer more to OCUL or TTRX?

Summary

How does Turn Therapeutics compare to ANI Pharmaceuticals?

Is TTRX or ANIP more profitable?

Does the media prefer TTRX or ANIP?

Do institutionals & insiders hold more shares of TTRX or ANIP?

Which has stronger valuation & earnings, TTRX or ANIP?

Do analysts rate TTRX or ANIP?

Summary

How does Turn Therapeutics compare to Rapport Therapeutics?

Do analysts recommend RAPP or TTRX?

Is RAPP or TTRX more profitable?

Does the media prefer RAPP or TTRX?

Which has stronger valuation & earnings, RAPP or TTRX?

Summary

How does Turn Therapeutics compare to GH Research?

Does the media favor TTRX or GHRS?

Is TTRX or GHRS more profitable?

Do institutionals & insiders have more ownership in TTRX or GHRS?

Which has better earnings and valuation, TTRX or GHRS?

Do analysts recommend TTRX or GHRS?

Summary

How does Turn Therapeutics compare to Innoviva?

Do insiders and institutionals believe in TTRX or INVA?

Which has stronger valuation and earnings, TTRX or INVA?

Does the media refer more to TTRX or INVA?

Do analysts prefer TTRX or INVA?

Is TTRX or INVA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TTRX vs. The Competition

Turn Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools